ZNF410 is a zinc finger transcription factor that functions as a highly selective regulator of fetal hemoglobin (HbF) expression in erythroid cells 12. Unlike typical transcription factors that regulate numerous genes, ZNF410 uniquely dedicates itself to activating a single target: CHD4, a core component of the NuRD chr14 remodeling complex 12. ZNF410 binds to two evolutionarily conserved clusters containing 27 combined binding motifs near the CHD4 locus with no counterparts elsewhere in the genome 2. This binding recruits the SWI/SNF complex to maintain chr14 accessibility and enhance CHD4 expression 3. By activating CHD4, ZNF410 indirectly represses the fetal globin genes HBG1 and HBG2, maintaining their silenced state in adult erythroid cells 12. Loss of ZNF410 reduces CHD4 levels by approximately 60%, sufficient to substantially de-repress HbF while avoiding cellular toxicity 2. Clinically, ZNF410 represents a promising therapeutic target for β-hemoglobinopathies, as its inhibition can reactivate HbF expression to ameliorate sickle cell disease and thalassemia 45. Recent evidence demonstrates that CHD4-associated enhancer RNAs modulate this regulatory pathway, adding complexity to the epigenetic mechanisms controlling hemoglobin switching 6.